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ABSTRACT: Introduction: Myotonia congenita (MC) is caused by
congenital defects in the muscle chloride channel CLC-1. This
study used muscle velocity recovery cycles (MVRCs) to investigate
how membrane function is affected. Methods: MVRCs and
responses to repetitive stimulation were compared between 18
patients with genetically confirmed MC (13 recessive, 7 dominant)
and 30 age-matched, normal controls. Results:MC patients exhib-
ited increased early supernormality, but this was prevented by
treatment with sodium channel blockers. After multiple conditioning
stimuli, late supernormality was enhanced in all MC patients, indi-
cating delayed repolarization. These abnormalities were similar
between the MC subtypes, but recessive patients showed a
greater drop in amplitude during repetitive stimulation. Conclu-
sions: MVRCs indicate that chloride conductance only becomes
important when muscle fibers are depolarized. The differential
responses to repetitive stimulation suggest that, in dominant MC,
the affected chloride channels are activated by strong depolariza-
tion, consistent with a positive shift of the CLC-1 activation curve.
Muscle Nerve 49: 845–857, 2014
Myotonia congenita (MC) is an hereditary disor-
der characterized by delayed muscle relaxation and
stiffness after voluntary activation. It is caused by
mutations of the CLCN1 gene, which encodes the
skeletal muscle chloride channel CLC-1. Over 100
different CLCN1 mutations causing myotonia have
been described.1 Inheritance is autosomal domi-
nant or recessive; in general, autosomal recessive
myotonia congenita (ARMC), or Becker myotonia,
is more severe clinically than autosomal dominant
myotonia congenita (ADMC), or Thomsen disease.
However, mutation-specific variations in phenotype
are well recognized, and phenotypic variation even
within the same family can be wide,2 suggesting that
epigenetic factors may be involved.
In both ARMC and ADMC, loss of function
mutations affecting the CLC-1 channel result in a
reduction in chloride conductance.3 Myotonic dis-
charges are thought to arise because a cumulative
afterdepolarization, or depolarizing afterpotential,
which occurs with repetitive activity, becomes large
enough to trigger self-maintaining activity.4 This
depolarizing afterpotential was shown to arise in
the t-tubule system and was attributed to accumula-
tion of potassium ions. In normal muscle fibers it
is kept to safe limits by high chloride conductance.
The chloride conductance provides an electrical
buffering effect, which helps keep the membrane
potential close to its resting level, as chloride ions
are distributed almost passively and the chloride
equilibrium potential is therefore close to the rest-
ing potential.5
Although studies of nerve membrane excitabil-
ity are now well established, until recently, in vivo
studies of muscle excitability have proven more
problematic. Previously described single-fiber
methods were time-consuming and exhibited con-
siderable variability.6 In 2009, Bostock and Z’Grag-
gen developed a modified technique, which
measures the velocity recovery cycles of a group of
adjacent muscle fibers.7 These multifiber record-
ings have been applied successfully in several clini-
cal conditions including renal failure,8 critical
illness myopathy,9 and muscle ischemia secondary
to postural hypotension.10 We have recently per-
formed additional studies to assess the validity of
this method for testing muscle membrane proper-
ties and found the method to be robust.11 This
technique is now being applied to patients with a
variety of channelopathies affecting muscle func-
tion. For this purpose, the scope of the tests has
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been broadened by adding 2 repetitive stimulation
protocols,12 because muscle activation is known to
precipitate muscle dysfunction in some muscle dis-
orders.13–15 The first of these studies described
altered muscle membrane function in patients
with Andersen–Tawil syndrome, a rare type of peri-
odic paralysis due to defective inward rectifier
channels.16
In this study, multifiber muscle velocity recovery
cycles (MVRCs) and a repetitive stimulation proto-
col12,16 were used to explore the characteristics of the
excitability properties of the sarcolemma in patients
with MC and to determine whether the excitability
measures were helpful in understanding the differ-
ence between the ADMC and ARMC subtypes. The
early and late phases of supernormality in MVRCs are
thought to be related directly to the early and late
depolarizing afterpotentials of muscle fibers7,17; there-
fore, it was anticipated that MVRCs would provide a
good indication of the exaggerated afterpotentials
responsible for myotonic discharges in MC patients.
METHODS
Patients. All 18 patients had chloride channel
mutations and were classified as having myotonia con-
genita (MC); they were aged 46.66 13.8 years
(mean6 SD), range 23 to 72 years (Table 1). Of these
18 patients, 7 were classified as autosomal dominant
(ADMC; patients 1–7 in Table 1) and 11 as autosomal
recessive (ARMC; patients 8–18), based on a combina-
tion of family history and the results of genetic analy-
ses. Several of the patients were being treated with
sodium channel modulators (mexiletine, carbamaze-
pine, quinine sulfate) to help control their myotonia
(Table 2). To enable testing for possible effects of
drug treatment on muscle properties, the patients
were divided into those considered on-treatment
(designated Rx1) and those considered off-treatment
(Rx2, i.e., untreated or last dose >5 half-lives of the
drug before testing). Six of the ARMC and 5 of the
ADMC patients were in the Rx2 category.
Controls. The activity-dependent velocity changes
were compared with recordings from 30 normal
controls (NC): 19 women and 11 men, aged
41.96 14.7 years (range 21–67 years), including 20
from a previous study.12
Consent. Informed written consent was obtained
from all patients and controls according to the
Declaration of Helsinki. This study was approved
by the research ethics committee of St Thomas’
Hospital, London, UK, and Kantonal Ethikkommis-
sion, Bern, Switzerland.
Study Protocol. All patients had muscle velocity
studies; the short exercise test at room tempera-
ture; and a blood sample for electrolytes, calcium,
and magnesium taken at the end of the session
(within 2 h of the studies). These patients had
already had routine nerve conduction studies and
muscle sampling performed for diagnostic
Table 1. Patients-clinical and demographic data.
Pt Diagnosis Amino acid change Gender Age (y)
Clinical features (Y/N)
TW Falls Painful stiffness
1 ADMC Gly230Glu W 55 N N N
2 ADMC Gly230Glu M 63 N N N
3 ADMC Gly230Glu W 46 N N N
4 ADMC Ala313Val W 38 N N N
5 ADMC Ala313Val M 72 N N N
6 ADMC Ala313Thr W 39 N N N
7 ADMC Gly551Asp M 33 N N N
8 ARMC Val327Ile (1); Arg894X M 51 Y Y N
9 ARMC c.18013 A>T (1); Gly190Arg W 54 Y N N
10 ARMC c.18013 A>T (1); Gly190Arg M 50 Y N N
11 ARMC Gly285Glu† M 23 N N N
12 ARMC Glu624fs† M 43 N N Y
13 ARMC Arg105Cys; Phe167Leu (1) Glu624fs M 24 N N N
14 ARMC c.18013 A>T homozygous M 49 N N Y
15 ARMC c.147111 G>A (1); Arg894X W 43 N N N
16 ARMC Homozygous intronic mutation M 67 N Y N
17 ARMC Gly276Ser (1); Pro480fs M 33 N Y Y
18 ARMC Gly285Glu (1); Met485Val W 48 N N N
Pt, patient; ADMC, autosomal dominant myotonia congenita; ARMC, autosomal recessive myotonia congenita; TW, transient weakness.
†Considered to be a recessive mutation based on family and functional studies. This patient has had the entire coding sequence of the CLCN1 gene
(encompassing consensus splice sites) analysed along with rearrangement analysis to detect exonic deletion/duplications, and only this mutation was
detected. We cannot exclude mutations in regulatory sequences elsewhere within the gene.
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purposes prior to entry to this study. None had a
neuropathy or myopathic changes on EMG.
Short Exercise Test. Short exercise tests (SETs)
were performed by stimulating the ulnar nerve at
the wrist and recording with surface electrodes
over abductor digiti minimi, as described by
Streib18 and Fournier et al.14 Compound muscle
action potentials (CMAPs) were recorded at base-
line and every 10 s during 3 short exercise trials
(10-s exercise followed by 60-s rest). The amplitude
changes from baseline were calculated and plotted
as described previously.15 We used amplitude-only
changes, because cooling was not performed. Nor-
mative data for amplitude-only decrement at room
temperature (n5 51, upper limit of normal
11.5%) was obtained from controls tested
previously.15
Muscle Velocity Recordings. Experimental Setup. The
recording technique was similar to that developed
for the brachioradialis muscle,7 but adapted to tibi-
alis anterior (TA).12,16 Recordings were performed
on the distal third of TA, with a monopolar stimu-
lating needle inserted perpendicularly within 1 cm
of the palpated distal extent of the muscle. Stimu-
lation currents were delivered through an insu-
lated monopolar needle electrode (28G; TECA,
Viasys Healthcare, Madison, Wisconsin) inserted to
a depth of 6–8 mm, and a non-polarizable surface
electrode (Kendall Q-trace; Tyco Healthcare
Group, UK) placed distal and laterally on the mus-
cle served as the anode. Rectangular pulses (0.05
ms) generated by a computer were converted to
current with an isolated constant-current stimula-
tor (DS5; Digitimer, Ltd., Welwyn Garden City,
Hertfordshire, UK). Muscle activity was recorded
with a concentric needle electrode (disposable
30G concentric EMG needle, Cardinal Health,
Madison, Wisconsin) approximately 20 mm proxi-
mal to the stimulating needle. The ground elec-
trode (Kendall, as above) was positioned between
the stimulating and recording electrodes. Surface
temperature over TA was recorded at the end of
the recording.
The signal was amplified (gain 1000, bandwidth
1.6 HZ to 2 kHZ) and digitized (NIDAQ-6062E;
National Instruments Europe Corp., Debrecen,
Hungary) using a sampling rate of 20 kHZ. The
electrodes were adjusted to obtain a stable negative
peak response with a stimulus of 3–10 mA. Stimu-
lation and recording were controlled by Qtrac soft-
ware (VC Institute of Neurology, University College
London, London, UK), using the 1200RCMQ.QRP
recording protocol.
Muscle Velocity Recovery Cycles at Rest. MVRCs
were recorded with 1, 2, and 5 conditioning stim-
uli, all separated by 10-ms interstimulus intervals
(ISIs). Test stimuli were delivered every 2 s. The
Table 2. Patients-electrophysiology and medication
Pt Diagnosis SET pattern*
SET RT abnormal
(Y/N)†
Maximum amplitude
decrement % Medication‡ Rx‡
1 ADMC 2 Y 95 (Mexiletine) –
2 ADMC 3 N 0 Mexiletine 1
3 ADMC 3 N 0 None –
4 ADMC 2 N 5 None –
5 ADMC 3 N 0 Mexiletine 1
6 ADMC 2 Y 28 None –
7 ADMC 3 N 0 None –
8 ARMC 2 Y 45 (Quinine sulfate) –
9 ARMC 2 Y 71 Mexiletine 1
10 ARMC 2 Y 69 Mexiletine 1
11 ARMC 3 N 7 Mexiletine 1
12 ARMC 2 Y 12 (Mexiletine) –
13 ARMC 2 Y 25 (Mexiletine) –
14 ARMC 2 Y 39 Carbamazepine, quinine sulfate 1
15 ARMC 2 Y 35 None –
16 ARMC 2 Y 40 Mexiletine 1
17 ARMC 2 Y 25 None –
18 ARMC 2 Y 31 None –
Pt, patient; ADMC, autosomal dominant myotonia congenita; ARMC, autosomal recessive myotonia congenita; SET, short exercise test; RT, room tempera-
ture; Y, yes; N, no.
*SET pattern as described in Fournier et al.14 Pattern 1: decrement without recovery during the 60s rest period, typically worsening with consecutive exer-
cise trials; pattern 2: Transient decrement with recovery during each 60s rest period; often becoming less marked with subsequent exercise trials; pattern
3: no decrement.
†Upper limit of normal for amplitude-only decrement at room temperature5 11.5% (Tan et al.15)
‡Medication in parentheses and Rx designated (2) if the medication had been omitted for >5 times the half life (T1=2) of the drug at the time of the study
(T1=2 mexilitine 10212 h, T1=2 quinine sulfate 12218 h, T1=2 carbamazepine 35240 h).
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ISI between the last conditioning stimulus and the
test stimulus was varied from 1000 to 1.4 ms in 34
steps in an approximately geometric series (specifi-
cally 1000, 900, 800, 700, 600, 500, 450, 400, 350,
300, 260, 220, 180, 140, 110, 89, 71, 56, 45, 35, 28,
22, 18, 14, 11, 8.9, 7.1, 5.6, 4.5, 3.5, 2.8, 2.2, 1.8,
and 1.4 ms).
Frequency Ramp. To characterize the effects of
progressive muscle activation, the test stimulus was
preceded by a 1-s train of stimuli at a frequency
that was increased by 1 HZ on successive 2-s cycles
from 1 to 30 HZ. The average stimulation rate was
therefore increased from 0.5 to 15.5HZ over 1 min.
Stimulus cycles with the test stimulus alone were
recorded before (10 cycles at 0.5 HZ), during the
ramp, and for a further 30 s after the end of the
ramp.
Data Analysis. Recovery cycle data were ana-
lyzed by the QtracP program, as described previ-
ously.7 The waveforms were first filtered with
digital high-pass (100 HZ cut-off) and low-pass (500
HZ) filters applied both in forward and reverse
time directions to provide baseline stabilization
and smoothing without time displacement.11
Response latencies were then measured from the
start of the test stimulus to the negative peak of
the muscle action potential. The effects of 1, 2,
and 5 conditioning pulses on the latency of the
test response were calculated as percentage differ-
ences compared with the latency of the test stimu-
lus alone.
Several excitability measures were derived from
the 2 recording protocols:
(a) VRCs at rest (Fig. 1). The MRRP was defined
as the earliest (interpolated) ISI at which the laten-
cies of the conditioned and unconditioned test
responses were identical. Early supernormality
(ESN) was measured as the largest percentage
decrease in latency for ISIs below 15 ms. Late
supernormality (LSN) was the mean percentage
decrease in latency for ISIs between 50 and 150
ms. Compared with previous MVRC studies, we
additionally defined “supernormality at 20 ms”
(SN20) as the mean of supernormalities at 18 and
22 ms, 5ESN as the early supernormality after 5
conditioning impulses, and “residual super-
normality” (RSN) as the mean percentage decrease
in latency at the end of the sweep, averaged for
ISIs of 900 and 1000 ms. We also defined the
“extra” supernormalities 2XLSN and 2XRSN as the
differences between the percentage latency
decreases for 2 and 1 conditioning stimuli, and
5XLSN and 5XRSN as the differences between the
percentage latency decreases for 5 and 1 condi-
tioning stimuli.
(b) Frequency ramp. The measurements made
during the frequency ramp are presented in Figure
2. They were the latency of the negative peak of
FIGURE 1. Recovery cycle measurements used for data analysis. Recovery cycles with 1 and 5 conditioning stimuli, and their differ-
ence, plotted on linear (A) and logarithmic (B) interstimulus interval (ISI) scales for a single patient with myotonia congenita. The mus-
cle relative refractory period (MRRP), early supernormality (ESN), and late supernormality (LSN) are as defined previously, and 5ESN
is the peak early supernormality after 5 conditioning stimuli. Because recovery is incomplete at 1 s in myotonia, we also defined resid-
ual supernormality (RSN) between ISIs of 900 and 1000 ms. 5XLSN and 5XRSN are the extra supernormalities after 5 conditioning
impulses, taken from the difference plots. Differences between 2 and 1 conditioning pulses were calculated similarly as 2XLSN and
2XRSN (not illustrated).
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the muscle action potential, expressed as a per-
centage of baseline latency recorded at 15 HZ
[Lat(15HZ)] and 30 HZ [Lat(30HZ)] during the
ramp. Latency changes were different for the first
and last responses in each 1-s train of action poten-
tials, and these are indicated by the subscripts
“First” and “Last,” respectively, so that Lat(15H-
Z)First was the latency to the first of 15 conditioning
pulses, expressed as a percentage of baseline. Val-
ues of Lat(30HZ)Last are not given, because this
quantity was found to be unmeasurable in many
patients when the responses became too small.
Action potential peak amplitudes were recorded
similarly as percentages of baseline values:
Peak(15HZ)First; Peak(15HZ)Last; Peak(30HZ)First;
and Peak(30HZ)Last. In all cases, the latency meas-
urements during the frequency ramp first
decreased and then increased again, describing a
U-shaped trajectory, and the frequency at which
the latency was minimal (determined by fitting a
quadratic to each 6 adjacent points) was denoted
FLatMin, again with the subscript First or Last.
Statistics. Many of the activity-dependent conduc-
tion measures failed the Lilliefors test of normality,
and also the variances of several measures differed
widely between groups. For intergroup compari-
sons we therefore applied the Welch unequal var-
iance t-test to the ranked data,19 and for
correlations between measures we used the Spear-
man rho (q). When comparing groups with multi-
ple t-tests or correlations, only P< 0.01 was
considered significant, but in Tables 3 and 4,
P< 0.05 is marked as significant for convenience
in assessing individual tests.
RESULTS
Velocity recovery cycles with 2 and 5 condition-
ing stimuli were recorded successfully from all
patients and controls, followed by the frequency
ramp protocol, and (in the case of the patients
only) by the short exercise test. Surface tempera-
tures over TA were very similar between controls
(mean6 SD: 30.56 0.9) and patients (30.76 1.0)
and were not significantly different between any of
the patient subgroups.
Short Exercise Test. The results of the short exer-
cise tests at room temperature are detailed in
Table 2. The short exercise test performed on the
day of the muscle excitability studies was suggestive
of chloride channel myotonia in 2 of 7 patients
with ADMC and in 10 of 11 patients with ARMC.
Velocity Recovery Cycles. The results of the
MVRCs with 1 and 5 conditioning stimuli are pre-
sented in Figures 3 and 4, and the measurements
are compared in Table 3. In the unmedicated
(MCRx2) patients the early increase in velocity
(ESN) following a single impulse was 14% greater
than in control subjects (Fig. 3A), and the increase
after 5 conditioning impulses was 21% greater;
these abnormalities were not seen in the patients
on sodium channel blockers. Another difference
between the Rx1 and Rx2 groups was in the time
at which supernormality peaked [i.e., ESN@(ms);
Table 3], which was 2.4 ms later in the medicated
group. The supernormality reflects the depolariz-
ing afterpotential after an impulse, which is
thought to arise because inward charge movement
(mostly sodium ions) exceeds outward charge
movement (mostly potassium ions) during the
action potential. The membrane depolarization
decays over about 1 s, as this charge on the capaci-
tance of the sarcolemmal and t-tubule capacitance
leaks away. Because chloride channels are generally
considered to be responsible for most of the rest-
ing membrane conductance and because of the
well-established reduction in chloride conductance
in myotonia congenita, we expected the supernor-
mality to last appreciably longer in the patients,
but this was not the case (Fig. 3A). It was only
when 2 conditioning stimuli were delivered that
there was a clear prolongation of supernormality
FIGURE 2. Frequency ramp measurements. Changes in
latency and peak of muscle action potentials in a patient with
myotonia congenita during the frequency ramp protocol, in
which a 1-s train of impulses was given every 2 s. During the
period of the frequency ramp, separate measurements were
made of the responses to the first and last stimulus in the train.
Small circles indicate points measured when intermittent stimu-
lation was at 15 or 30 HZ, and also the frequencies when
latency was minimal; for example, Lat(15HZ)First(%)5 percent-
age change in latency of first response in train, when frequency
reached 15 HZ, FLatMinLast(HZ)5 frequency when the latency
to the last response in the train was minimal.
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Table 3. Velocity recovery cycle measurements compared between groups.
NC
(n530) MC (n518) MCRx2 (n511) MCRx1 (n57) MCRx2 vs. MCRx1
MRRP (ms) 3.506 0.47 3.4760.89 3.1760.27 3.9661.30 P 5 0.11 (NS)
P 5 0.27 (NS) P 5 0.024* P 5 0.51 (NS)
ESN (%) 12.16 2.2 13.062.1 13.86 1.9 11.86 1.8 P 5 0.016*
P 5 0.12 (NS) P 5 0.016* P 5 0.82NS
ESN@(ms) 7.76 1.0 8.661.9 7.760.6 10.16 2.3 P 5 0.00012‡
P 5 0.048* P 5 0.80 (NS) P 5 5.2 3 1025§
5ESN (%) 14.56 2.7 15.962.7 17.56 1.3 13.36 2.3 P 5 4.5 3 1025§
P 5 0.065 (NS) P 5 4.7 3 1025§ P 5 0.29 (NS)
SN20 (%) 7.06 1.4 9.261.5 9.461.7 9.060.9 P 5 0.47 (NS)
P 5 9.9 3 1027j P 5 3.8 3 1025§ P 5 0.00014‡
LSN (%) 4.076 0.90 4.4960.74 4.8560.43 3.9460.80 P 5 0.020*
P 5 0.10 (NS) P 5 0.0012† P 5 0.60NS
RSN (%) 0.166 0.24 0.1960.44 0.1460.45 0.5660.28 P 5 0.024*
P 5 0.22 (NS) P 5 0.75 (NS) P 5 0.00030‡
2XLSN (%) 2.796 0.85 3.3360.60 3.2660.56 3.4360.69 P 5 0.89 (NS)
P 5 0.0055† P 5 0.033* P 5 0.0075†
2XRSN(%) 0.266 0.20 0.6460.32 0.5960.23 0.7160.42 P 5 0.69 (NS)
P 5 2.5 3 1026j P 5 0.00025‡ P 5 5.1 3 1025§
5XLSN (%) 8.006 1.51 9.5161.27 10.116 0.75 8.5761.40 P 5 0.010*
P 5 0.00036‡ P 5 1.9 3 1027j P 5 0.37 (NS)
5XRSN(%) 1.166 0.51 2.7560.57 2.8360.65 2.6360.43 P 5 0.44 (NS)
P 5 2.5 3 10212j P 5 6.2 3 10210j P 5 7.7 3 10211j
First column shows values obtained from tibialis anterior muscle in 30 normal control subjects (NC). Next 3 columns show values obtained from all 18
patients with myotonia congenita (MC), the component subgroups of 11 that were off treatment (MCRx2), and 7 that were on sodium channel blockers
(MCRx1). Values given are mean6SD, and P-value is for Welch rank test (non-parametric unequal variance t-test) for difference in median from normal
controls. Last column shows P-values for comparison between MC subgroups: NS, not significant;
*P< 0.05,
†P< 0.01,
‡P< 0.001,
§P< 0.0001,
jP< 0.00001.
Table 4. Frequency ramp.
NC (n5 30) MCRx2 (n5 11) MCRx1 (n5 7) MCRx2 vs. MCRx1 ADMC (n57) ARMC (n5 11) ADMC vs. ARMC
Lat [15 Hz]First (%) 93.26 2.9 89.06 3.5 92.26 6.2 P 5 0.19 (NS) 91.26 2.6 89.565.9 P 5 0.40 (NS)
P 5 0.00012‡ P 5 0.77 (NS) P 5 0.11 (NS) P 5 0.023*
Lat [15 Hz]Last (%) 83.36 3.6 82.76 10.8 94.9614.0 P 5 0.0029
† 81.56 5.0 91.36 15.6 P 5 0.19 (NS)
P50.11 (NS) P 5 0.014* P 5 0.37 (NS) P 5 0.41 (NS)
Lat [30 Hz]First (%) 94.16 3.5 93.86 2.6 96.96 4.9 P 5 0.92 (NS) 93.96 3.6 95.764.1 P 5 0.25 (NS)
P 5 0.77 (NS) P 5 0.15 (NS) P 5 0.82 (NS) P 5 0.26 (NS)
FreqLatMinFirst (Hz) 20.96 3.4 18.16 2.7 15.26 6.3 P 5 0.16 (NS) 19.36 3.8 15.564.6 P 5 0.092 (NS)
P 5 0.017* P 5 0.043* P 5 0.40 (NS) P 5 0.00026‡
FreqLatMinLast (Hz) 18.76 2.8 14.06 2.0 11.26 2.3 P 5 0.0057
† 14.16 2.3 12.262.4 P 5 0.16 (NS)
P 5 5.1 3 1027jP 5 5.0 3 10210j P 5 1.1 3 1025§P 5 4.2 3 1029j
Peak [15 Hz]First (%)115.86 11.2 114.26 28.2 96.7653.0 P 5 0.56 (NS) 129.76 25.7 93.26 40.6 P 5 0.054 (NS)
P 5 0.94 (NS) P 5 0.66 (NS) P 5 0.20 (NS) P 5 0.17 (NS)
Peak [15 Hz]Last (%)104.16 18.6 84.26 52.6 60.0655.9 P 5 0.35 (NS) 119.26 40.1 46.56 40.9 P 50.0011
P 5 0.33 (NS) P 5 0.26 (NS) P 5 0.18 (NS) P 5 0.00085‡
Peak [30 Hz]First (%)118.36 13.7 117.16 25.0 110.26 47.2 P 5 0.92 (NS) 134.86 32.3 101.5629.7 P 5 0.046*
P 5 0.78 (NS) P 5 0.94 (NS) P 5 0.12 (NS) P 5 0.10 (NS)
Peak [30 Hz]Last (%) 90.26 24.7 47.46 35.9 42.3651.8 P 5 0.47 (NS) 77.36 37.0 25.26 30.4 P 5 0.012*
P 5 0.0023† P 5 0.10 (NS) P 5 0.50 (NS) P 5 1.0 3 1025§
Effects of frequency ramp on latencies and amplitudes of muscle action potentials. The first 4 columns and figures correspond to those in Table 3. The last
3 columns show a similar comparison between 7 dominant and 11 recessive MC patients. P-values below means and SDs are for Welch rank test for dif-
ference in median values from normal controls, and P-values in last column compare MC subtypes. P-values as in Table 3.
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(Fig. 3B and C), and the measures of late and
residual supernormality were very different
between patients and controls (Table 3).
Although the recovery from depolarization
occurred at a similar rate in patients and controls
close to the resting potential, there was a short-
lived slowing in recovery for MC patients com-
pared with controls between about 10 and 100 ms.
This is seen more clearly with a logarithmic ISI
axis (Fig. 4A), so that supernormality at 20 ms
(SN20: arrow) was distinctly greater in the MC
patients (Table 3), whether on medication or not.
Figure 4B shows that the medication only affected
the earliest part of the recovery cycles. The later
parts were also indistinguishable between the myo-
tonia ADMC and ARMC subgroups (Fig. 4C). The
apparent difference in peak supernormality was
not significant, and in fact none of the MVRC
FIGURE 3. Muscle velocity recovery cycles. MVRCs for 11 myotonia congenita patients not on medication (filled black circles) and 30
normal controls (open gray circles) are compared for 1 (A), 2 (B), and 5 (C) conditioning stimuli. Data points show means with single
standard error bar.
FIGURE 4. Muscle velocity recovery cycles of MC subgroups. A: MVRCs for 11 untreated MC patients (filled black circles) and 30 nor-
mal controls (open gray circles) replotted on a logarithmic timebase. Data points show means with single standard error bar. (B) Com-
parison between 11 MCRx2 (black filled circles) and 7 MCRx1 patients on sodium channel medication (gray open circles). (C)
Comparison between myotonia subgroups (5 ADMC5Thomsen type; 5 ARMC5Becker type), restricted to those not on medication.
Top row: percentage latency change after single conditioning impulse; middle row: additional latency change after a second condition-
ing impulse; bottom row: difference in percentage latency change after 5 conditioning impulses from latency change after single condi-
tioning impulse. The arrow in (A) indicates ISI of 20 ms at which NC and MC latency changes diverged significantly. There were no
differences between the ADMC and ARMC patients with this protocol.
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measurements after 1–5 conditioning stimuli dif-
fered significantly between the ADMC and ARMC
patients.
Frequency Ramp. The results of increasing the
stimulation rate from an average of 1 HZ to 15 HZ
(i.e., 30 HZ for 1 s with interval of 1 s) are illus-
trated in Figure 5, and measurements obtained as
shown in Figure 2 are listed in Table 4. In this
test, all groups exhibited a U-shaped latency curve,
with initial speeding giving way to relative slowing
of conduction, probably because progressive depo-
larization, due to potassium accumulation in the t-
tubules, caused sodium channel inactivation. In
Figure 5A the MCRx2 group went “round the U”
more rapidly than the controls, and the additional
depolarization caused a reduction in peak ampli-
tude, because the reduced chloride conductance
was inadequate to maintain the membrane poten-
tial. (In some MC patients, the last responses in
each train even became too small at the higher fre-
quencies to measure their latency, and thus laten-
cies to the last response in each train are omitted
in Fig. 5.) The most sensitive measure to discrimi-
nate between the MCRx2 and NC groups was Freq-
LatMinLast (Table 4 and Fig. 5B), the frequency at
which the latency U reached a minimum for the
last response in the train. This measure was
reduced even more with sodium channel medica-
tion, but as with the other latency measurements it
did not distinguish between the ADMC and ARMC
subgroups. In contrast, the changes in peak ampli-
tude during the frequency ramp did not differ sig-
nificantly between the MCRx1 and MCRx2 groups,
but the amplitude of the last response in the train
[i.e., Peak(15HZ)Last and Peak(30HZ)Last] was
reduced much more for ARMC than ADMC
patients (Table 4). Figure 5C shows that, although
the latency changes in ADMC and ARMC patients
started off decreasing together, at about 10 HZ
they began to diverge, and the ADMC action
potentials did not drop in amplitude as much as
those in the ARMC group (the early increase in
amplitude in the ADMC group was not statistically
significant).
Comparison with Conventional Short Exercise
Test. When the amplitude decrements in the
short exercise test were compared with the other
measurements for the 18 myotonia patients, the
strongest correlation was with Peak(30HZ)Last%,
the peak amplitude of the response to the last
stimulus in the 30HZ train at the end of the fre-
quency ramp, and the next best correlations were
with Peak(15HZ)Last% and Peak(15HZ)First%, the
amplitudes of the last and first responses in the
train at 15 HZ. The values were not normally dis-
tributed, so the Spearman rho was used as a mea-
sure of correlation, which was 20.761 for Peak
(30HZ)Last% (P5 0.00028), 20.684 (P5 0.0018)
for Peak(15HZ)Last%, and 20.617 (P5 0.0063) for
Peak(15HZ)First%. The relationships between 2 of
these measurements of activity-dependent ampli-
tude change and SET decrement are illustrated in
FIGURE 5. Frequency ramp. Responses of myotonia congenita patients to frequency ramp protocol, compared with those from normal
controls. Muscles were stimulated for 1 s every 2 s at frequencies from 1 to 30 HZ. (A) Eleven MCRx2 patients, plotted in black, com-
pared with 30 normal controls, plotted in gray (means only). (B) Comparison between 11 MCRx2 (black) and 7 MCRx1 patients (gray).
(C) Five ARMCRx2 patients (black) compared with 5 ADMCRx2 patients (gray). First row: latency as percent of control for the first
response in each train; second row: peak amplitude as a percent of control for the last response in each train; third row: stimulation
rate during the train.
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Figure 6. The close relationship between SET dec-
rement and the frequency ramp measures holds
for patients on sodium channel blockers as well as
for untreated patients. It will be noted that ARMC
patients tend to have greater SET decrements and
peak amplitude changes during the frequency
ramp than ADMC patients, and the SET decre-
ments and frequency ramp peak changes are the
physiological measures that best distinguish ADMC
from ARMC patients. However, whereas the P-value
for comparison between ADMC and ARMC
patients by the Welch rank test was 0.0022 for
Peak(15HZ)Last%, the same test applied to SET
decrement did not achieve significance
(P5 0.054).
Comparison between ADMC Patients and NC and
ARMC Groups. Because the muscle abnormalities
in all MC patients are attributed to dysfunctional
chloride channels, and the symptoms in ARMC
patients are usually more severe than those in
ADMC patients, it might be expected that activity-
dependent conduction changes would fall along a
single line, corresponding to the percentage of
available chloride channels, with ADMC intermedi-
ate between the NC and ARMC groups. One might
expect that the variables in Tables 3 and 4 that
best separate the NC and MC groups would be the
same variables that best separate the ADMC and
ARMC subgroups. Inspection of the tables, how-
ever, indicates that this is very far from the case. In
Figure 7, the NC, ADMC, and ARMC group values
are compared for the 3 variables that best separate
MC patients from controls and also for the 2 varia-
bles that best separate the MC subgroups. In Fig-
ure 7A–C, the MVRC variables, 5XRSN and SN20,
and the frequency ramp variable, FMinLatLast,
which are the variables that differ most between
the MC patients and controls, are not significantly
different between the ADMC and ARMC sub-
groups. Similarly, in Figure 7D and E, the variables
that are most different between the myotonia sub-
groups are not significantly different between the
ADMC subgroup and controls. These comparisons
suggest that the ADMC subgroup does not simply
express a milder form of the chloride channel dys-
function exhibited by the ARMC subgroup but
that it expresses a qualitatively distinct abnormality,
as discussed below.
DISCUSSION
In this study we have used direct muscle stimu-
lation and recording to explore whether activity-
dependent conduction changes can provide useful
information about the abnormal muscle mem-
brane properties in MC. Here we have discussed
the nature of the membrane changes revealed by
the new tests, the insights this provides into the
mechanisms underlying clinical myotonia and tran-
sient weakness in MC, and how some of these
changes are ameliorated by sodium channel block-
ers. We have also discussed the reasoning why dif-
ferent membrane properties should be associated
with the autosomal dominant and autosomal reces-
sive inheritance patterns.
Muscle Membrane Properties Underlying Myotonia in
MC. We found an increased early supernormality
(ESN) in our untreated MC patients compared
with normal controls (Table 3). The size of the
ESN reflects the size of the depolarizing afterpo-
tential (DAP) following the action potential (AP),
FIGURE 6. SET vs. frequency ramp. Comparison between amplitude decrement measured in the short exercise test and the changes
in peak amplitude of responses during the frequency ramp: (A) Last response in train at 15 HZ; and (B) last response in train at 30
HZ. Circles5 7 ADMC patients; triangles5 11 ARMC patients; filled symbols5Rx2, open symbols5Rx1. Also indicated are regres-
sion lines of peak amplitudes on SET decrement and Spearman rank correlation coefficients (q) for all 18 patients (**P<0.01;
***P<0.001).
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and the increased ESN in our patients is consistent
with the DAP being larger due to reduced chloride
conductance. In sustained myotonic discharges,
the typical intraburst interval is 6.5–50 ms (intra-
burst frequency 20–150 HZ20), so it is of interest
that supernormality was enhanced most signifi-
cantly at 20 ms (Table 3). In addition, in MC
patients, there was an increase in late supernormal-
ity (LSN), which was amplified after a train of
impulses (Table 3 and Figs. 3 and 4). This late
supernormality is thought to reflect the depolariz-
ing effects of K accumulation in the t-tubules,7
which in MC patients is larger due to loss of the
normal buffering effect of chloride conductance.
The recovery is also delayed after multiple condi-
tioning stimuli, so that 5XRSN, the extra residual
supernormality 1 s after 5 conditioning impulses,
provides the most consistently abnormal feature of
the MVRCs in MC patients (Table 3). It is likely
that the cumulative late supernormality is relevant
not only to facilitating repetitive firing after an AP,
but also in sustaining prolonged trains of myotonic
discharges. Augmentation of hyperexcitability after
a rapid train of impulses may explain why clinical
myotonia is more severe after a sudden strong con-
traction (e.g., when attempting a sprint) compared
with a gentle limb movement.
Muscle Membrane Properties Underlying Transient
Weakness in MC. When the loss of chloride con-
ductance is severe, the depolarization caused by
the increase in LSN after a sustained train of
impulses may be sufficient to inactivate Na chan-
nels, thus leading to failure to generate APs and
therefore weakness. This is illustrated by our find-
ings during the frequency ramp, where in the
ARMC patients, a rapid train of impulses (15 HZ)
was associated with a fall in amplitude of the com-
pound muscle fiber response, analogous to the fall
in CMAP in the short exercise test. This is dis-
cussed in more detail later when comparing
ADMC with ARMC.
How Does Medication with Sodium Channel Blockers
Reduce Myotonia in MC?. We were unable to test
the same patients on and off drug, so we can only
make limited inferences about the effects of medi-
cation. Nevertheless, our recordings provide some
insights into how sodium channel blockers reduce
myotonic discharges in patients with MC. Figure
4B indicates that the principal effects of Na chan-
nel blockade were to reduce the peak supernor-
mality and delay its onset, and this reduction was
more pronounced after a train of 5 impulses. In 6
of 7 cases, the Na channel blocker was mexiletine,
FIGURE 7. ADMC data compared with NC and ARMC. Activity-dependent conduction measures, plotted as medians and interquartile
ranges, for those variables which best distinguish MC patients from normal controls (A–C) and for those variables which best separate
ADMC and ARMC subgroups (D–E). P-values are indicated for comparisons between adjacent groups by the Welch rank test
(NSP>0.05, *P<0.05, **P<0.01, ****P<0.0001, *****P<0.00001). Note the overlap between the ADMC and ARMC groups in (A)–
(C) and overlap between the NC and ADMC groups in (D)–(E).
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whereas the patient on carbamazepine and quinine
exhibited qualitatively similar differences from the
drug-free group. The results suggest that the block-
ade results in delayed and reduced opening of Na
channels during the AP, causing delayed and
reduced DAP and associated supernormality. These
observations are consistent with the effects of mexi-
letine on wild-type Nav1.4 channels in vitro21 and
provide some insights into how Na channel block-
ade may alleviate myotonia in MC patients,
because the effect on ESN is counter to that of
reduced chloride conductance. In addition, as Na
channel blockade did not appear to affect the
increase in late supernormality after a train of
impulses (5XLSN and 5XRSN; Table 3), this may
explain why Na channel blockers are only partially
effective in relieving myotonia in patients with MC.
Na channel blockade also did not appear to affect
peak amplitudes, so that the differences between
the ADMC and ARMC subgroups in the bottom
part of Table 4 were similar if only untreated
patients were averaged (Fig. 5C).
MVRCs and Resting Chloride Conductance. It is
often stated that chloride channels are responsible
for 80–85% of the resting membrane conductance
of skeletal muscle fibers.1,2,22,23 Assuming that chlo-
ride conductance is reduced by at least half in MC
patients (since heterozygous carriers of recessive
mutations are asymptomatic), the figure of 80%
implies that resting membrane conductance should
be reduced by at least 40% and membrane time
constant increased by at least 60% in the patients.
The results in Figure 3A, however, show no such
evidence. Decay of supernormality after a single
impulse, presumably reflecting decay of the depola-
rizing afterpotential, was very similar to normal.
Only after 2 or 5 impulses was the decay to baseline
notably slowed (Fig. 4B and C). Further light was
shed on this unexpected behavior by Figure 4A, in
which it is seen that for a period up to about 100
ms after a single impulse, the supernormality was
distinctly greater in patients with MC, a difference
that was highly significant at 20 ms (Table 3). This
suggests that the chloride channels only played a
major role in normalizing the membrane potential
for a limited period after the action potential,
whereas the membrane was still depolarized. Con-
sistent with this, when the supernormality was sup-
plemented by the prominent late afterpotential
after 5 conditioning impulses, as potassium ions
accumulated in the t-tubule system, the chloride
channels were clearly active again in the normal
subjects, because, in the patients, the late afterpo-
tential was relatively enhanced and prolonged.
The explanation for this unexpected behavior
is that resting chloride conductance is much lower
than once thought. The figure of 85% of resting
membrane conductance was obtained from in vitro
preparations, in which the resting potentials meas-
ured with sharp electrodes averaged about 275
mV,24,25 whereas in vivo recordings from human
muscle fibers showed a normal resting potential of
291 mV in a previous study.26 This discrepancy in
resting potentials is important, because muscle
chloride channels are voltage-dependent; they
deactivate on hyperpolarization and activate on
depolarization.27 Furthermore, intracellular adeno-
sine triphosphate (ATP) levels were not controlled
in the in vitro experiments, and the high level of
ATP in resting muscle effectively inhibits CLC-1
activity by shifting voltage gating to more positive
potentials.28 A recent in vitro study with internal
ATP controlled, showed that resting muscle chlo-
ride conductance was just under 10% of maximum
at 290 mV and increased steeply with membrane
depolarization, with a time constant of about 10
ms.29 The recordings in Figures 3 and 4 support
this model, in which chloride channel conduct-
ance is quite low in the resting state, but increases
during the early part of the DAP (e.g., at 20 ms),
with a time lag because of the slow kinetics. After
5 action potentials the cumulative late afterpoten-
tial becomes large enough to provide prolonged
chloride channel activation, the lack of which is
evident in MC patients. Therefore, the CLC-1 chlo-
ride channels should not be thought of as simple
leakage channels, but as channels that act specifi-
cally to limit membrane depolarization.
Repetitive Stimulation and Separation of ADMC from
ARMC. It has long been recognized that some MC
patients have a decrementing CMAP response to
repetitive stimulation, which correlates with pres-
ence of transient weakness rather than with the
severity of myotonia30–33 A large decrement in
response to 10-HZ repetitive stimulation is gener-
ally thought to be characteristic of ARMC, similar
to the large decrements in the short exercise test,
although there are exceptions.34 Accordingly, in
our frequency ramp recordings, there was a separa-
tion of the MC subtypes. This was seen most clearly
in the decline in peak amplitude for the last
response in each train of the frequency ramp,
which was much more pronounced for the ARMC
group, both at 15 and 30 HZ (Table 4 and Fig. 5).
As suggested above, the decline in peak amplitude
presumably occurred because there was insufficient
time between trains to clear the potassium accu-
mulation in the t-tubules, resulting in a progressive
membrane depolarization and resultant inactiva-
tion of sodium channels. This potassium-driven
membrane depolarization is normally limited by
activation of the high chloride conductance, so the
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observation that the action potentials dropped in
amplitude during the ramp much more for the
ARMC patients than the ADMC patients suggests
that, in this situation, effective chloride conduct-
ance was lower in the former group.
Why Should Chloride Channels Behave Differently in
Myotonia Subgroups?. Our recordings indicate
that ADMC and ARMC muscles behave similarly
when depolarized by up to 5 stimuli, but that
ARMC muscles become more depolarized during
long trains of impulses. The implication that chlo-
ride conductance is increased by depolarization in
ADMC muscles is consistent with current ideas
about the structure of chloride channels and their
mutations in MC. The CLC-1 channels are now
known to be dimers with 2 pores which are con-
trolled by 2 gates in series: a “common gate,”
which affects current through both pores, and 2
independent “fast gates,” which each control cur-
rent through a single pore.23 ADMC is associated
with mutations affecting the common gate, usually
by shifting its voltage dependence so that more
depolarization than normal is needed to open the
channel.35–37 In ARMC, on the other hand, the
mutations usually affect only a fast gate, but with
both alleles affected total loss of function may
result.23
There are exceptions to these generalizations,
because the same mutation can apparently cause
ADMC in one family and ARMC in another,38 but
they provide a simple explanation for our findings.
In ADMC and ARMC, chloride conductance at rest
and on mild depolarization can be similarly
reduced, resulting in the comparable MVRC
abnormalities shown in Figure 7A–C. However,
when subjected to long trains of impulses and pro-
gressive membrane depolarization due to potas-
sium accumulation, the common gates of the
chloride channels in ADMC patients are opened,
thus limiting the extent of membrane depolariza-
tion. Whereas the depolarization in ARMC patients
causes reduced muscle action potentials and can
be sufficient to reduce calcium release and cause
weakness, in ADMC the depolarization is self-
limiting, and there is no weakness.
In conclusion, we have found that MVRCs pro-
vide evidence of an enhanced depolarizing afterpo-
tential in MC patients, which may help trigger
myotonic discharges, but it is counteracted by
sodium channel blockers. The MVRCs contradict
the idea that CLC-1 channels provide the major
component of resting membrane conductance;
depolarization is required to activate the CLC-1
channels and to reveal the reduced chloride con-
ductance in MC patients. The ADMC and ARMC
subgroups had very similar MVRCs, but the decline
in amplitude during the frequency ramp, which
correlates with the amplitude decrement in the
short exercise test, was much greater in the ARMC
than in the ADMC patients. This is most likely
because the CLC-1 mutation in ADMC does not
totally inactivate the channels but only shifts the
voltage dependence of the common gate, so that
the channels become activated when depolarized,
and depolarization is self-limiting.
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